Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder
ICD-10 F16.95 is a billable code used to indicate a diagnosis of hallucinogen use, unspecified with hallucinogen-induced psychotic disorder.
F16.95 refers to a condition characterized by the use of hallucinogenic substances that leads to a psychotic disorder. Hallucinogens, such as LSD, psilocybin, and mescaline, can cause significant alterations in perception, mood, and cognitive processes. When an individual experiences psychotic symptoms—such as hallucinations, delusions, or disorganized thinking—due to hallucinogen use, it is classified under this code. The unspecified nature indicates that the specific hallucinogen used is not documented. This condition can lead to severe impairment in social and occupational functioning and may require immediate intervention. Treatment often involves a combination of psychiatric care, substance use disorder therapy, and supportive measures to ensure the safety and stabilization of the patient. Understanding the nuances of this diagnosis is crucial for effective treatment and accurate coding.
Detailed psychiatric evaluations, including history of substance use and mental status examinations.
Patients presenting with acute psychosis following hallucinogen use, requiring stabilization and psychiatric intervention.
Consideration of co-occurring mental health disorders and the need for integrated treatment plans.
Comprehensive substance use history, including patterns of use and previous treatment attempts.
Patients in withdrawal from hallucinogens or those seeking treatment for hallucinogen use disorder.
Focus on harm reduction strategies and the need for ongoing support and counseling.
Used for follow-up visits for patients diagnosed with hallucinogen-induced psychotic disorder.
Documentation must include a review of symptoms, treatment response, and any changes in mental status.
Psychiatrists should ensure comprehensive mental health assessments are documented.
F16.95 is used when hallucinogen use leads to psychotic symptoms, while F16.94 is used when it leads to mood disorders. The distinction lies in the primary symptoms experienced by the patient.
